A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by activating the mother’s immune system to generate defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection offers newborns with instant defence from the moment of birth, precisely when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent coverage when immunised 4 weeks before birth
- Antibodies from the mother passed through the placenta safeguard newborns from day one
- Protection possible with two-week gap before premature birth
- Vaccination during third trimester still provides meaningful protection for infants
Strong evidence from the latest research
The effectiveness of the RSV vaccine administered during pregnancy has been confirmed through a thorough investigation undertaken in England, examining data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month timeframe, providing robust and representative information of the vaccine’s real-world impact. The study’s conclusions have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The breadth of this investigation offers healthcare professionals and parents-to-be with confidence in the vaccine’s proven efficacy across diverse populations and circumstances.
The results paint a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This marked difference emphasises the vaccine’s vital importance in protecting against serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The sizeable sample and thorough nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology measured real-world outcomes rather than controlled laboratory conditions, providing real-world data of how the vaccine performs when delivered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the hazards
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection causes deep inflammation in the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed adequately. Parents frequently observe their babies struggling visibly, their chests rising whilst they work to get enough air into their compromised lungs. Whilst most newborns get better with clinical support, a limited though important group succumb from RSV complications yearly, making prevention through vaccination a critical public health priority for protecting the most vulnerable and youngest members of society.
- RSV triggers lung inflammation, resulting in severe breathing difficulties in infants
- Nearly 50% of newborns contract the infection in their first few months of life
- Symptoms span from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK babies require serious hospital care for RSV annually
- A small number of babies succumb to RSV complications annually in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have stressed the value of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for ensuring newborns receive the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery offers nearly 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies via the placenta.
The guidance from health authorities remains clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has reassured pregnant women that protection is still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.
Regional differences in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These geographical variations demonstrate variations in medical facilities, communication strategies, and community involvement initiatives, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts launching varied communication campaigns to connect with expectant mothers
- Geographic variations in vaccine uptake rates across England require targeted improvement
- Local healthcare systems modifying schemes to suit local requirements and situations
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness provides real advantages for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this protective measure, the 80% decrease in admissions means thousands of infants shielded from serious illness. Parents no more face the upsetting situation of watching their newborns labour to breathe or labour to feed, symptoms that define serious RSV disease. The vaccine has fundamentally shifted the landscape of neonatal respiratory health, giving expectant mothers a preventative option to protect their most vulnerable children during those critical early months.
For families like that of Malachi, whose acute RSV infection resulted in severe brain damage, the vaccine’s availability carries deep personal significance. His mother’s advocacy for the jab emphasises the transformative consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such grave complications—hospitalisation, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to expectant mothers navigating their late pregnancy, transforming what was once an unavoidable seasonal threat into a manageable health risk.